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Aberrant activation of the Hedgehog (Hh) signaling pathway contributes to many forms of cancer. Primary
cilia are Hh signal transduction centers. Two papers in a recent issue of Nature Medicine (Han et al., 2009;
Wong et al., 2009) show that mutating cilia can increase or reduce the rates of tumorigenesis depending
on how the Hh pathway is disrupted.In a victory for a small and once neglected
organelle, two papers recently published
in Nature Medicine now demonstrate
that brain and skin tumors dependent on
Hedgehog (Hh) signaling are regulated
by primary cilia (Han et al., 2009; Wong
et al., 2009). Erudite cell biologists have
known for a long while that most cell types
in our bodies have these singular immotile
appendages (Berbari et al., 2009).
Genetic damage to primary cilia results
in a spectrum of problems classified as
ciliopathies. The diseases can have
a range of effects, including blindness
and improper brain development (Sharma
et al., 2008). Primary cilia are important
for proper Hh signaling (Figure 1), and at
least some ciliopathy-associated prob-
lems can now be attributed to disrupted
Hh signal transduction.
Motile cilia have familiar active physio-
logic roles, such as clearing air passages
and moving cerebrospinal fluid through
ventricles in the brain. In contrast, primary
cilia are moved rather than movers,
transducing signals in response to fluid
flow in kidneys or in response to mechan-
ical bone deformation. Cilia consist of
a plasma membrane sheath containing
a microtubule-based axoneme with nine
peripheral microtubule doublets and no
central pair ofmicrotubules. The axoneme
extends from the basal body, which arises
from a centriole taking time off from cell
division. When cells reenter the cell cycle,
the centriole must return to its role in cell
division, and primary cilia are disas-
sembled. These intermittently present
cell-surface organelles contain a rich
collectionof proteins, aswell asmysteries.
Kif3a and Ift88 encode cilium compo-
nents. Kif3a encodes a kinesin that is276 Cancer Cell 16, October 6, 2009 ª2009employed for transport along the microtu-
buleaxoneme fromthebaseof cilia toward
their tips. Because protein synthesis does
not occur in cilia, this anterograde trans-
port is crucial in formation and main-
tenance of the organelle. Mice lacking
Kif3a function lack cilia, die early in embry-
onic development, and exhibit deficient
left-right patterning (Marszalek et al.,
1999). Ift88 encodes a component of the
intraflagellar transport machinery that is
required for cilium formation. Ift88 protein
is present in basal bodies and cilia in
nondividing cells, and in centrosomes
during cell division (Robert et al., 2007).
Mice lacking Ift88 functiondie inmidgesta-
tion. Their defects include left-right asym-
metry, cilium malformation, and neural-
tube abnormalities (Murcia et al., 2000).
Key features of Hh signaling were ini-
tially worked out in Drosophila, an organ-
ism in which Hh-transducing cells lack
primary cilia. Appreciation of the involve-
ment of cilia in vertebrate Hh signaling
has provoked new questions about cell
biology mechanisms. When Hh pathway
restraint systems are damaged, cancer
can arise in tissues where Hh target genes
normally stimulate cell division. The Hh
pathway was first connected to cancer
when Gorlin syndrome was found to be
due to loss of Ptc receptor function. Loss
of Ptc function allows Smo activity to go
unchecked, thus leading to excessive
activation of Hh target genes that promote
cell division. The consequences, in Gorlin
syndrome, include basal cell carcinoma
(BCC) of the skin and medulloblastoma
(MB) of the cerebellum, as well as skeletal
and other defects.
The two new papers exploit another
route to tumorigenesis—constitutivelyElsevier Inc.active Smo protein encoded by the
SmoM2 allele that is capable of causing
cancer despite normal Ptc protein
activity. In the first paper, Wong and
colleagues showed that human and
mouse skin tumor cells have cilia, at least
some of the time, as does normal mouse
skin. The authors generated conditional
SmoM2 mice that enable tamoxifen-
inducible, skin-restricted production of
the SmoM2 protein. After tamoxifen treat-
ment at age 30 days, hyperactive SmoM2
was produced. Within 5 wks, mice began
to exhibit epidermal hyperplasia and a
premalignant lesion, and substantial pen-
etrating growths into the dermis appeared
by 10–20 wks. When Cre was used to
produce SmoM2 and at the same time
inactivate a floxed allele of Kif3a in skin
cells, BCC tumorigenesis was blocked.
The skin and tumors of these mice had
few cilia, as expected.
The Gli2 transcription factor acts down-
stream of Smo in the skin, so the authors
further investigated the role of Kif3a in
tumorigenesis, using a mouse model
employing inducible constitutively active
Gli2 with a mutation in the N-terminal
repressor domain of the protein (Gli2DN).
Gli2DN, behaving as a constitutively
active protein, raises the levels of endog-
enous Gli2. Here came the big surprise:
tumorigenesis was accelerated in the
absence of cilia. Evidently, cilia can nor-
mally restrain the activity of this abnormal
form of Gli2. The use of Gli2DN makes
the implications for typical tumorigenesis
unclear, but the results could imply that
sequestration of normal Gli2 in cilia limits
its ability to go off and cause trouble in
the nucleus. Cilia are also needed to
generate a repressing form of Gli3 (GliR).
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Figure 1. Hedgehog Signal Transduction in Development and Cancer
In the Hh pathway, binding of Hh ligand to the Patched (Ptc) 12-transmembrane domain receptor
unleashes the 7-transmembrane domain protein Smoothened (Smo) to direct the formation of activating
transcription factors, Gli proteins, that trigger target gene expression. Intracellular transport events occur
during Hh transduction. In the absence of Hh ligand (A), Ptc is in cilia and Smo is largely outside cilia. Gli
transcription factors are, remarkably, present in cilia. Processing of Gli proteins can give rise to repressor
forms that go to the nucleus and repress target genes. When Hh ligand arrives at the primary cilium (B), it
binds Ptc, and together they leave the cilia. The absence of Ptc from cilia, either upon Hh binding or when
ptc is mutated, allows Smo to move into cilia, where it is evidently capable of triggering processing and
transport of activating Gli transcription factor forms to the nucleus. Constitutive Smo activity in SmoM2
mutant cells (C) leads to activation of Gli transcription factors and target gene expression, even in the
absence of Hh ligand.Thus, Gli3Rmay restrain Gli2DN in ciliated
cells. When cilia are not formed, Gli3R
cannot be produced and Gli2DN has
added destructive potency. How Gli2DN
interacts with normal Gli proteins is
unclear.
The second paper applies a similar
strategy to the analysis of MB, a less
frequent but more deadly tumor often
seen in Gorlin syndrome patients. The
paper reports the presence of cilia in
human MBs. To test the roles of cilia in
MB, Han and colleagues expressed the
constitutively active SmoM2 allele or the
Gli2DN construct, using human glial fibril-
lary acidic protein (hGFAP) promoter-
driven Cre, which directs expression of
Cre in granule neuron precursors (GNPs)
of the cerebellum, among other primitive
neural cells. By postnatal day 10, prior to
complete development of the cerebellum,
mice with hGFAP-driven SmoM2 expres-
sion expanded their GNP population and
formed tumors. Normally, GNPs prolif-
erate under the influence of Sonic hedge-
hog signal emanating from Purkinje
neurons, and GNPs are thought to be
the cell type of origin for MBs.In the new work, removal of Kif3a and
Ift88, and the consequent loss of cilia,
blocked normal proliferation of GNPs and
tumorigenesis. In contrast to hGFAP-
driven SmoM2 expression, activation of
the Hh pathway with the use of hGFAP-
driven Gli2DN expression failed to induce
MBs. Gli2DN transgenic mice developed
brain tumors only after removal of Kif3a
and primary cilia; just as in BCCs,
Gli2DN-triggered tumorigenesis is en-
hanced. Brain tumors in these hGFAP-
driven Gli2DN and SmoM2 mice differed
from each other and from Gorlin
syndrome tumors arising from Patched
haploinsufficiency. SmoM2 mutant mice
have tumors that encase the entire cere-
bellum as a result of rapid malignant
transformation of all GNPs, as compared
to Gorlin syndrome tumors, in which
a discrete tumor forms from a small pop-
ulation of GNPs. A subset of Gli2DN
tumors (termed type 1 tumors) resembles
MB. hGFAP-Gli2DN mice also develop
a somewhat mysterious second type of
central nervous system tumor, which
can be located in the cerebellum, brain-
stem, or cerebrum and is histologicallyCancer Cell 1distinct from MB. The significance of
type 2 tumors, and their relevance to Hh
signaling and human disease, remains
unclear.
Thus, the character of skin and neuron
precursor cells can be dramatically
transformed by tiny tails that exert a
disproportionately large influence on cell
fates. Developmental signaling pathways,
including Hedgehog, Wnt, TGFb, and
Notch, have been implicated in oncogen-
esis, so their constituent proteins have
become candidates for new cancer drug
targets. Recent papers have demon-
strated the utility of Smo antagonists in
Hh-driven human tumors, including BCC
and MB (Rudin et al., 2009; Von Hoff
et al., 2009; Yauch et al., 2009). The two
recent Nature Medicine papers highlight
the intriguing potential of primary cilia
components as alternative targets for
antitumor drugs, but they underscore the
challenges of manipulating an organelle
that has positive and negative effects on
pathway activity and tumorigenicity.
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